Skip to main content
. 2005 Oct;73(10):6383–6389. doi: 10.1128/IAI.73.10.6383-6389.2005

FIG. 5.

FIG. 5.

(a) ELISA titration (IgG, IgM) of human convalescent-phase sera on a GASP-HSA (compound 8)-coated plate. OD 450 nm, optical density at 450 nm. (b) Inhibition of human convalescent-phase serum 1 with GAS inhibitors on a GASP-HSA (compound 8)-coated plate. (c) Inhibition of human convalescent-phase serum 2 with GAS inhibitors on a GASP-HSA (compound 8)-coated plate. (d) Inhibition of human convalescent-phase serum 1 with GAS inhibitors on a hexasaccharide-BSA (compound 4)-coated plate. (e) Inhibition of human convalescent-phase serum 2 with GAS inhibitors on a hexasaccharide-BSA (compound 4)-coated plate. The numbers for the symbols indicate compounds shown in Fig. 1.